There is a possible impact on survival after Abiraterone resistance.
Abiraterone is primarily a drug used to treat advanced prostate cancer, usually in combination with prednisone. In itself, advanced tumor treatment drugs are limited, if the patient develops resistance to the drug, then it may affect the condition, resulting in poor control of the disease and affecting the prognosis.
Therefore, this kind of patients who are resistant to abiraterone may have limited clinical treatments, and if distant metastasis is more dangerous, there is a possibility that their lives will be in danger in a short period of time.
Abiraterone belongs to the oncology specialty drugs, it is recommended to use under the guidance of oncologists, and if resistance occurs, it is recommended to carry out a comprehensive assessment and adjust the drug regimen if necessary.